We utilized microarray technology to conduct a Pan-therapy Analysis and identify two key gene signatures (DAPP1 and ELL2) as biomarkers of unresponsiveness to multiple therapies and inflammatory progression in IBD. The gene discussed is DAPP1; the disease is inflammatory bowel disease.